On Monday, 2 June, the Swiss pharmaceutical group, Roche, announced that it had just purchased the Californian Company, Genia, which specialises in DNA sequencing. The cost of this acquisition: 125 million dollars.

Created in 2009, Genia “is developing technology which should reduce the cost of DNA sequencing whilst improving its rapidity of execution and precision“.